Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Gilead Sciences, Inc.    GILD   US3755581036


SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

05/11/2012 | 03:06pm US/Eastern
   By Jennifer Corbett Dooren 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294;

Recommend :
React to this article
Latest news on GILEAD SCIENCES, INC.
1d agoDJMARKET SNAPSHOT : Long View On Stocks Is Best During Weak Earnings Season
3d ago EXCLUSIVE : Biogen prices hemophilia drug on par with older therapies
3d ago GILEAD SCIENCES : Sets Date to Release 1Q 2014 Results
4d ago WALL STREET WEEK AHEAD : Spring fever brings hope for U.S. earnings
4d ago Analysis - Fidelity biotech fund among worst performers in April sell-off
4d ago BRISTOL MYERS SQUIBB : Reports Submission of New Drug Application to U.S. FDA fo..
4d ago GILEAD SCIENCES : Highlights Study Results on Sovaldi
5d ago GILEAD SCIENCES : Announces Results from Study of Sovaldi® for Retreatment of Ch..
5d ago GILEAD SCIENCES : Announces Phase 2 Results for Two Investigational All-Oral Sof..
5d ago GILEAD SCIENCES : Sovaldi® Demonstrates Efficacy and Safety Among Chronic Hepati..
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Income Statement Evolution
Gilead Sciences, Inc. : Income Statement Evolution
More Financials
Dynamic quotes